An international market entry model for pharmaceutical companies: A conceptual framework for strategic decisions

Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing

Volumn 3, Issue 4, 2003, Pages 274-286

  Javalgi, Rajshekhar G ^a   Wright, Robert F ^b  

^a CLEVELAND STATE UNIVERSITY   (United States)

^b NONE

Author keywords

foreign markets; global; international; market entry; pharmaceutical; strategies

Indexed keywords

EID: 84990380699     PISSN: 17457904     EISSN: 17457912     Source Type: Journal    
DOI: 10.1057/palgrave.jmm.5040131     Document Type: Article

References (70)

1. Louie L. (2001) ‘A prescription for profits’, Upside, May, 102–107.
2. Yuguan W. Song J. (1999) ‘China: A future star for foreign pharma companies’, Pharmaceutical Executive, 19, 78–87.
3. Pharmaceutical Executive.
4. Gopal K. (1999) ‘Policy & price’, Pharmaceutical Executive, 19, 30–32.
5. Wechsler J. (1999) ‘World affairs’, Pharmaceutical Executive, 19, 18–24.
6. Thayer A. M. (1999) ‘Drug producers post increased sales, earnings’, Chemical & Engineering News, 77, 33–34.
7. Wechsler J. (1999) Chemical & Engineering News.
8. (1999) ‘Experts predict growing revenue, greater expense in global market’, Medical Marketing and Media, 34, 18.
9. Medical Marketing and Media.
10. Yuguan W. Song J. (1999) Medical Marketing and Media.
11. Steinert B.W. (1998) ‘Harmonisation: International rules coming to a planet near you’, SRA Journal, 30, 69–71.
12. Milmo S. (1998) ‘ICH seeks common ground’, Chemical Market Reporter, 254, FR19–FR21.
13. Chemical Market Reporter.
14. Chaudhry P. Dacin P. (1997) ‘Strategic planning in a regulated trade bloc: The pharmaceutical industry in the European Union’, European Management Journal, 15, 686–697.
15. Wechsler J. (1999) European Management Journal.
16. European Management Journal.
17. European Management Journal.
18. Sterman A. B. (1998) ‘Competitive advantage through medical marketing excellence’, Pharmaceutical Executive, 18, 108–120.
19. Yuguan W. Song J. (1999) Pharmaceutical Executive.
20. Pharmaceutical Executive.
21. Prahalad C.K. Lieberthal K. (1998) ‘The end of corporate imperialism’, Harvard Business Review, 76, 69–79.
22. Harvard Business Review.
23. Yuguan W. Song J. (1999) Harvard Business Review.
24. Harvard Business Review.
25. Wechsler J. (1999) Harvard Business Review.
26. Milmo S. (1998) Harvard Business Review.
27. Wechsler J. (1999) Harvard Business Review.
28. Milmo S. (1998) Harvard Business Review.
29. Gopal K. (1999) Harvard Business Review.
30. Yuguan W. Song J. (1999) Harvard Business Review.
31. Wechsler J. (1999) Harvard Business Review.
32. Torres C. (1999) ‘Argentina IS tricky ground for U.S. drug makers: Lax enforcement of treaty causes a loss of sales’, The Wall Street Journal, 3rd December, A13.
33. Wechsler J. (1999) The Wall Street Journal.
34. Prahalad C.K. Lieberthal K. (1998) The Wall Street Journal.
35. Shama A. (1995) ‘Entry stategies of U.S. firms to the newly independent states, Baltic states, and Eastern European countries’, California Management Review, 37, 90–109.
36. Levy A. (2001) ‘Cross-border mergers: Promises unfulfilled’, Bloomberg Markets, April, 37–46.
37. Sauer P. (1998) ‘Finding the next blockbuster drug’, Chemical Market Reporter, 254, FR3–FR6.
38. Scott A. (1999) ‘Drug makers consolidate’, Chemical Week, 161, 29.
39. Heracleous L. Murray J. (2001) ‘The urge to merge in the pharmaceutical industry’, European Management Journal, 19, 430–437.
40. Mangan D. (1999) ‘Are biotech stocks finally ready to soar?’ Medical Economics, 76, 101–114.
41. Mirasol F. (1999) ‘Pharmaceutical industry sees more mergers and acquisitions’, Chemical Market Reporter, 256, 5, 14.
42. Langreth R. (1999) ‘Pfizer's Warner bid echoes need for staff,’ The Wall Street Journal, 19th November, A3.
43. Jacobs P. (1999) ‘Merger to create new biotech giant; health: Johnson&Johnson - Centocor deal comes as pharmaceutical firms seek growth areas’, The Los Angeles Times, 22nd July, 3.
44. Langreth R. (1999) The Los Angeles Times.
45. Mirasol F. (1999) The Los Angeles Times.
46. Koberstein W. (1999) ‘Celebration and labor: A new company's birthday’, Pharmaceutical Executive, 19, 44–64.
47. Louie L. (2001) Pharmaceutical Executive.
48. Koberstein W. (1999) Pharmaceutical Executive.
49. Pharmaceutical Executive.
50. Veitinger K. (1998) ‘Midsized Players—A model for the 21st century’, Pharmaceutical Executive, 18, 86–94.
51. Pharmaceutical Executive.
52. Shama A. (1995) Pharmaceutical Executive.
53. Pharmaceutical Executive.
54. Celestino M. L. (1999) ‘Pharmaceuticals, medical and biotechnology’, World Trade, 12, 98–102.
55. World Trade.
56. Van Arnum P. (1999) ‘Covance and Parexel International terminate proposed merger’, Chemical Market Reporter, 256, 13.
57. Celestino M. L. (1999) Chemical Market Reporter.
58. Shama A. (1995) Chemical Market Reporter.
59. Torres C. (1999) Chemical Market Reporter.
60. Shama A. (1995) Chemical Market Reporter.
61. Thompson A. (1999) ‘Biotech merger boosts IBT’, European Venture Capital Journal, 1st August, 10–11.
62. Louie L. (2001) European Venture Capital Journal.
63. European Venture Capital Journal.
64. Gopal K. (1997) ‘Global branding—Fancy or fact’, Pharmaceutical Executive, 17, 34–36.
65. Harris G. (1999) ‘Glaxo Wellcome eyes big market in stomach pain’, The Wall Street Journal, 16th November, B1, B4.
66. DeSimone G. (1998) ‘Overcoming obstacles to global branding’, Medical Marketing and Media, 33, 88–95.
67. Saldanha G. Pesanello P. Harrington E. (1997) ‘Building value through global branding’, Pharmaceutical Executive, 17, 72–80.
68. Chaudhry P. Dacin P. (1997) Pharmaceutical Executive.
69. Barrett A. Licking E. Carey J. Capell K. (1999) ‘Addicted to mergers: Deal making may not be the right prescription for drugmakers’, Business Week, 6th December, 84–90.
70. Louie L. (2001) Business Week.